ClinicalTrials.gg
CompletedNCT00515463Updated Oct 31, 2013Results posted

A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density

A Phase 3 interventional study of denosumab and denosumab in Low Bone Mineral Density, Osteopenia and Osteoporosis, sponsored by Amgen. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-10-31.

Primary conditionOsteoporosisRegistry: Bone Diseases, MetabolicReclassifiedWhy we changed it
Registry
Bone Diseases, Metabolic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoporosis
Why
  1. The study's listed conditions name Osteoporosis, a narrower term within Bone Diseases, Metabolic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
311
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.

Enrollment
13th of 64
311 · median 90
Started
2007
with 2 others
Phase 3
24 of 64
2 open now
Registered
9th of 64
by date
Lead sponsor
22 of 64
Amgen

Among the 64 studies testing denosumab in Osteoporosis, this one is the 13th largest by enrollment, is one of 3 that started in 2007, is one of 24 in phase 3, and was the 9th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing denosumab in Osteoporosis, or all of them as a file.
02

Study summary

The purpose of this study is to compare the immunogenicity profiles of denosumab pre-filled syringe (PFS) and vial at 6 months in postmenopausal women with low bone mineral density (BMD).

03

Conditions studied

  • Low Bone Mineral Density
  • Osteopenia
  • Osteoporosis

Browse trials for

Keywords

  • Osteopenia
  • Osteoporosis
  • AMG 162
  • Postmenopausal
  • Pre-filled syringe
04

In context

Osteoporosis Reclassified

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

This study's enrollment of 311 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.

Browse Osteoporosis studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Osteoporosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Bone Diseases, Metabolic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have successfully completed the 20050141 study (NCT00330460):

    • Must have received all SC product administrations in 20050141
    • Must not have taken any proscribed therapies in 20050141
    • Subjects who were in the alendronate or denosumab treatment group are allowed
  • Provide signed before any study-specific procedures are conducted

Exclusion criteria

Exclusion Criteria:

  • Any disorder that, in the opinion of the investigator, may compromise the ability of the patient to give written and/or comply with study procedures including:

    • Any physical or psychiatric disorder
    • Or evidence of alcohol or substance abuse in the last 12 months
  • Any clinical evidence, in the medical judgement of the investigator, of the following medical conditions:

    • Impaired thyroid function (subsequent to treatment)
    • Impaired hepatic function
    • Impaired renal function
    • Rheumatoid Arthritis, Paget's disease, Cushing's disease, hyperprolactinemia, or cirrhosis of the liver
    • Known to have tested positive for , virus, or surface antigen
    • Any metabolic bone disease, eg, osteomalacia or osteogenesis imperfecta, which may interfere with the interpretation of the findings
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
311 participants (actual)

Study arms

  • Experimental
    Denosumab - Vial

    Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.

    Biological: denosumab

  • Experimental
    Denosumab - Prefilled syringe

    Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.

    Biological: denosumab

Interventions

07

What researchers measure

Primary outcomes

  1. Number of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 6

    An electrochemiluminescent bridging immunoassay was used to test blood samples for binding antibodies to denosumab.

    Time frame: 6 months

Secondary outcomes

  1. Number of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 12

    An electrochemiluminescent bridging immunoassay was used to test blood samples for binding antibodies to denosumab.

    Time frame: 12 months

  2. Number of Participants With Neutralizing Antibodies Against Denosumab at Month 12

    Samples demonstrating reactivity for binding antibodies to denosumab were to be tested for neutralizing or inhibitory effects in a cell-based bioassay.

    Time frame: Month 12

  3. Sodium Change From Baseline at Month 1

    Laboratory chemistry sodium

    Time frame: Baseline, month 1

  4. Sodium Change From Baseline at Month 6

    Laboratory chemistry sodium

    Time frame: Baseline, month 6

  5. Sodium Change From Baseline at Month 12

    Sodium Change From Baseline at Month 12

    Time frame: Baseline, Month 12

  6. Potassium Change From Baseline at Month 1

    Laboratory chemistry potassium

    Time frame: Baseline, month 1

  7. Potassium Change From Baseline at Month 6

    Laboratory chemistry potassium

    Time frame: Baseline, month 6

  8. Potassium Change From Baseline at Month 12

    Laboratory chemistry potassium

    Time frame: Baseline, month 12

  9. Chloride Change From Baseline at Month 1

    Laboratory chemistry chloride

    Time frame: Baseline, month 1

  10. Chloride Change From Baseline at Month 6

    Laboratory chemistry chloride

    Time frame: Baseline, month 6

  11. Chloride Change From Baseline at Month 12

    Laboratory chemistry chloride

    Time frame: Baseline, month 12

  12. Bicarbonate Change From Baseline at Month 1

    Laboratory chemistry bicarbonate

    Time frame: Baseline, month 1

  13. Bicarbonate Change From Baseline at Month 6

    Laboratory chemistry bicarbonate

    Time frame: Baseline, month 6

  14. Bicarbonate Change From Baseline at Month 12

    Laboratory chemistry bicarbonate

    Time frame: Baseline, month 12

  15. Magnesium Change From Baseline at Month 1

    Laboratory chemistry magnesium

    Time frame: Baseline, month 1

  16. Magnesium Change From Baseline at Month 6

    Laboratory chemistry magnesium

    Time frame: Baseline, month 6

  17. Magnesium Change From Baseline at Month 12

    Laboratory chemistry magnesium

    Time frame: Baseline, month 12

  18. Blood Urea Nitrogen Change From Baseline at Month 1

    Laboratory chemistry blood urea nitrogen

    Time frame: Baseline, month 1

  19. Blood Urea Nitrogen Change From Baseline at Month 6

    Laboratory chemistry blood urea nitrogen

    Time frame: Baseline, month 6

  20. Blood Urea Nitrogen Change From Baseline at Month 12

    Laboratory chemistry blood urea nitrogen

    Time frame: Baseline, month 12

  21. Creatinine Change From Baseline at Month 1

    Laboratory chemistry creatinine

    Time frame: Baseline, month 1

  22. Creatinine Change From Baseline at Month 6

    Laboratory chemistry creatinine

    Time frame: Baseline, month 6

  23. Creatinine Change From Baseline at Month 12

    Laboratory chemistry creatinine

    Time frame: Baseline, month 12

  24. Aspartate Amino Transferase Change From Baseline at Month 1

    Laboratory chemistry aspartate amino transferase

    Time frame: Baseline, month 1

  25. Aspartate Amino Transferase Change From Baseline at Month 6

    Laboratory chemistry aspartate amino transferase

    Time frame: Baseline, month 6

  26. Aspartate Amino Transferase Change From Baseline at Month 12

    Laboratory chemistry aspartate amino transferase

    Time frame: Baseline, month 12

  27. Alanine Amino Transferase Change From Baseline at Month 1

    Laboratory chemistry alanine amino transferase

    Time frame: Baseline, month 1

  28. Alanine Amino Transferase Change From Baseline at Month 6

    Laboratory chemistry alanine amino transferase

    Time frame: Baseline, month 6

  29. Alanine Amino Transferase Change From Baseline at Month 12

    Laboratory chemistry alanine amino transferase

    Time frame: Baseline, month 12

  30. Total Bilirubin Change From Baseline at Month 1

    Laboratory chemistry total bilirubin

    Time frame: Baseline, month 1

  31. Total Bilirubin Change From Baseline at Month 6

    Laboratory chemistry total bilirubin

    Time frame: Baseline, month 6

  32. Total Bilirubin Change From Baseline at Month 12

    Laboratory chemistry total bilirubin

    Time frame: Baseline, month 12

  33. Albumin Change From Baseline at Month 1

    Laboratory chemistry albumin

    Time frame: Baseline, month 1

  34. Albumin Change From Baseline at Month 6

    Laboratory chemistry albumin

    Time frame: Baseline, month 6

  35. Albumin Change From Baseline at Month 12

    Laboratory chemistry albumin

    Time frame: Baseline, month 12

  36. Total Protein Change From Baseline at Month 1

    Laboratory chemistry total protein

    Time frame: Baseline, month 1

  37. Total Protein Change From Baseline at Month 6

    Laboratory chemistry total protein

    Time frame: Baseline, month 6

  38. Total Protein Change From Baseline at Month 12

    Laboratory chemistry total protein

    Time frame: Baseline, month 12

  39. Glucose Change From Baseline at Month 1

    Laboratory chemistry glucose

    Time frame: Baseline, month 1

  40. Glucose Change From Baseline at Month 6

    Laboratory chemistry glucose

    Time frame: Baseline, month 6

  41. Glucose Change From Baseline at Month 12

    Laboratory chemistry glucose

    Time frame: Baseline, month 12

  42. Red Blood Cells Change From Baseline at Month 1

    Laboratory hematology red blood cells

    Time frame: Baseline, month 1

  43. Red Blood Cells Change From Baseline at Month 6

    Laboratory hematology red blood cells

    Time frame: Baseline, month 6

  44. Red Blood Cells Change From Baseline at Month 12

    Laboratory hematology red blood cells

    Time frame: Baseline, month 12

  45. Hemoglobin Change From Baseline at Month 1

    Laboratory hematology hemoglobin

    Time frame: Baseline, month 1

  46. Hemoglobin Change From Baseline at Month 6

    Laboratory hematology hemoglobin

    Time frame: Baseline, month 6

  47. Hemoglobin Change From Baseline at Month 12

    Laboratory hematology hemoglobin

    Time frame: Baseline, month 12

  48. Reticulocytes Change From Baseline at Month 1

    Laboratory hematology reticulocytes

    Time frame: Baseline, month 1

  49. Reticulocytes Change From Baseline at Month 6

    Laboratory hematology reticulocytes

    Time frame: Baseline, month 6

  50. Reticulocytes Change From Baseline at Month 12

    Laboratory hematology reticulocytes

    Time frame: Baseline, month 12

  51. Platelets Change From Baseline at Month 1

    Laboratory hematology platelets

    Time frame: Baseline, month 1

  52. Platelets Change From Baseline at Month 6

    Laboratory hematology platelets

    Time frame: Baseline, month 6

  53. Platelets Change From Baseline at Month 12

    Laboratory hematology platelets

    Time frame: Baseline, month 12

  54. White Blood Cells Change From Baseline at Month 1

    Laboratory hematology white blood cells

    Time frame: Baseline, month 1

  55. White Blood Cells Change From Baseline at Month 6

    Laboratory hematology white blood cells

    Time frame: Baseline, month 6

  56. White Blood Cells Change From Baseline at Month 12

    Laboratory hematology white blood cells

    Time frame: Baseline, month 12

  57. Total Neutrophils Change From Baseline at Month 1

    Laboratory hematology total neutrophils

    Time frame: Baseline, month 1

  58. Total Neutrophils Change From Baseline at Month 6

    Laboratory hematology total neutrophils

    Time frame: Baseline, month 6

  59. Total Neutrophils Change From Baseline at Month 12

    Laboratory hematology total neutrophils

    Time frame: Baseline, month 12

  60. Eosinophils Change From Baseline at Month 1

    Laboratory hematology eosinophils

    Time frame: Baseline, month 1

  61. Eosinophils Change From Baseline at Month 6

    Laboratory hematology eosinophils

    Time frame: Baseline, month 6

  62. Eosinophils Change From Baseline at Month 12

    Laboratory hematology eosinophils

    Time frame: Baseline, month 12

  63. Basophils Change From Baseline at Month 1

    Laboratory hematology basophils

    Time frame: Baseline, month 1

  64. Basophils Change From Baseline at Month 6

    Laboratory hematology basophils

    Time frame: Baseline, month 6

  65. Basophils Change From Baseline at Month 12

    Laboratory hematology basophils

    Time frame: Baseline, month 12

  66. Lymphocytes Change From Baseline at Month 1

    Laboratory hematology lymphocytes

    Time frame: Baseline, month 1

  67. Lymphocytes Change From Baseline at Month 6

    Laboratory hematology lymphocytes

    Time frame: Baseline, month 6

  68. Lymphocytes Change From Baseline at Month 12

    Laboratory hematology lymphocytes

    Time frame: Baseline, month 12

  69. Monocytes Change From Baseline at Month 1

    Laboratory hematology monocytes

    Time frame: Baseline, month 1

  70. Monocytes Change From Baseline at Month 6

    Laboratory hematology monocytes

    Time frame: Baseline, month 6

  71. Monocytes Change From Baseline at Month 12

    Laboratory hematology monocytes

    Time frame: Baseline, month 12

  72. Number of Participants With Laboratory Toxicity CTCAE Grade Greater or Equal to 3

    Participants with laboratory toxicity grade 3 (severe) or 4 (life-threatening), based on the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.

    Time frame: Day 1 to Month 12

08

Results

Posted Oct 31, 2013

Participant flow

Patients who successfully completed Study 20050141 (NCT00330460) were eligible to participate in this study. First Subject Enrolled: 30-May-2007 Last Subject Enrolled: 10-Sep-2007

Participant flow — Overall Study
MilestoneDenosumab - VialDenosumab - Pre-filled Syringe
Started155156
Received study medication154156
Completed141142
Not completed1414
Withdrew: Physician decision42
Withdrew: Adverse event12
Withdrew: Withdrawal by subject34
Withdrew: Lost to follow-up65
Withdrew: Other01

Outcome measures

PrimaryNumber of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 6

An electrochemiluminescent bridging immunoassay was used to test blood samples for binding antibodies to denosumab.

Time frame:
6 months
Reported as:
Number · Participants
Number of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 6
ParticipantsDenosumab - VialDenosumab - Pre-filled Syringe
Number of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 600
Statistical analysis
  • Denosumab - Vial vs Denosumab - Pre-filled Syringe · Risk difference (rd): 0 · 95% CI -0.7 to 0.7Risk difference \> 0 indicates that incidence of binding anti-denosumab antibodies in denosumab PFS is greater than denosumab vial. 95% CI based on a normal approximation with continuity correction.
SecondaryNumber of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 12

An electrochemiluminescent bridging immunoassay was used to test blood samples for binding antibodies to denosumab.

Time frame:
12 months
Reported as:
Number · Participants
Number of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 12
ParticipantsDenosumab - VialDenosumab - Pre-filled Syringe
Number of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 1200
Statistical analysis
  • Denosumab - Vial vs Denosumab - Pre-filled Syringe · Risk difference (rd): 0 · 95% CI -0.7 to 0.7
SecondaryNumber of Participants With Neutralizing Antibodies Against Denosumab at Month 12

Samples demonstrating reactivity for binding antibodies to denosumab were to be tested for neutralizing or inhibitory effects in a cell-based bioassay.

Time frame:
Month 12

No measurements were reported for this outcome.

SecondarySodium Change From Baseline at Month 1

Laboratory chemistry sodium

Time frame:
Baseline, month 1
Reported as:
Mean · mmol/L
Sodium Change From Baseline at Month 1
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Sodium Change From Baseline at Month 1-0.1 ± 2.00.1 ± 1.7
SecondarySodium Change From Baseline at Month 6

Laboratory chemistry sodium

Time frame:
Baseline, month 6
Reported as:
Mean · mmol/L
Sodium Change From Baseline at Month 6
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Sodium Change From Baseline at Month 6-1.2 ± 2.0-0.9 ± 1.8
SecondarySodium Change From Baseline at Month 12

Sodium Change From Baseline at Month 12

Time frame:
Baseline, Month 12
Reported as:
Mean · mmol/L
Sodium Change From Baseline at Month 12
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Sodium Change From Baseline at Month 12-0.9 ± 2.1-0.6 ± 2.0
SecondaryPotassium Change From Baseline at Month 1

Laboratory chemistry potassium

Time frame:
Baseline, month 1
Reported as:
Mean · mmol/L
Potassium Change From Baseline at Month 1
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Potassium Change From Baseline at Month 10.02 ± 0.370 ± 0.39
SecondaryPotassium Change From Baseline at Month 6

Laboratory chemistry potassium

Time frame:
Baseline, month 6
Reported as:
Mean · mmol/L
Potassium Change From Baseline at Month 6
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Potassium Change From Baseline at Month 60.01 ± 0.43-0.07 ± 0.40
SecondaryPotassium Change From Baseline at Month 12

Laboratory chemistry potassium

Time frame:
Baseline, month 12
Reported as:
Mean · mmol/L
Potassium Change From Baseline at Month 12
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Potassium Change From Baseline at Month 120.07 ± 0.400.04 ± 0.40
SecondaryChloride Change From Baseline at Month 1

Laboratory chemistry chloride

Time frame:
Baseline, month 1
Reported as:
Mean · mmol/L
Chloride Change From Baseline at Month 1
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Chloride Change From Baseline at Month 1-0.1 ± 2.10.2 ± 1.9
SecondaryChloride Change From Baseline at Month 6

Laboratory chemistry chloride

Time frame:
Baseline, month 6
Reported as:
Mean · mmol/L
Chloride Change From Baseline at Month 6
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Chloride Change From Baseline at Month 6-0.9 ± 2.3-0.4 ± 2.0
SecondaryChloride Change From Baseline at Month 12

Laboratory chemistry chloride

Time frame:
Baseline, month 12
Reported as:
Mean · mmol/L
Chloride Change From Baseline at Month 12
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Chloride Change From Baseline at Month 12-0.2 ± 2.10 ± 2.5
SecondaryBicarbonate Change From Baseline at Month 1

Laboratory chemistry bicarbonate

Time frame:
Baseline, month 1
Reported as:
Mean · mmol/L
Bicarbonate Change From Baseline at Month 1
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Bicarbonate Change From Baseline at Month 1-0.3 ± 2.90 ± 2.9
SecondaryBicarbonate Change From Baseline at Month 6

Laboratory chemistry bicarbonate

Time frame:
Baseline, month 6
Reported as:
Mean · mmol/L
Bicarbonate Change From Baseline at Month 6
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Bicarbonate Change From Baseline at Month 60.2 ± 2.70.1 ± 2.9
SecondaryBicarbonate Change From Baseline at Month 12

Laboratory chemistry bicarbonate

Time frame:
Baseline, month 12
Reported as:
Mean · mmol/L
Bicarbonate Change From Baseline at Month 12
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Bicarbonate Change From Baseline at Month 12-0.6 ± 2.8-0.1 ± 2.8
SecondaryMagnesium Change From Baseline at Month 1

Laboratory chemistry magnesium

Time frame:
Baseline, month 1
Reported as:
Mean · mmol/L
Magnesium Change From Baseline at Month 1
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Magnesium Change From Baseline at Month 10.001 ± 0.092-0.010 ± 0.080
SecondaryMagnesium Change From Baseline at Month 6

Laboratory chemistry magnesium

Time frame:
Baseline, month 6
Reported as:
Mean · mmol/L
Magnesium Change From Baseline at Month 6
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Magnesium Change From Baseline at Month 6-0.053 ± 0.073-0.064 ± 0.080
SecondaryMagnesium Change From Baseline at Month 12

Laboratory chemistry magnesium

Time frame:
Baseline, month 12
Reported as:
Mean · mmol/L
Magnesium Change From Baseline at Month 12
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Magnesium Change From Baseline at Month 12-0.053 ± 0.062-0.055 ± 0.074
SecondaryBlood Urea Nitrogen Change From Baseline at Month 1

Laboratory chemistry blood urea nitrogen

Time frame:
Baseline, month 1
Reported as:
Mean · mmol/L
Blood Urea Nitrogen Change From Baseline at Month 1
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Blood Urea Nitrogen Change From Baseline at Month 10.01 ± 1.30-0.04 ± 1.38
SecondaryBlood Urea Nitrogen Change From Baseline at Month 6

Laboratory chemistry blood urea nitrogen

Time frame:
Baseline, month 6
Reported as:
Mean · mmol/L
Blood Urea Nitrogen Change From Baseline at Month 6
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Blood Urea Nitrogen Change From Baseline at Month 60.09 ± 1.400.11 ± 1.49
SecondaryBlood Urea Nitrogen Change From Baseline at Month 12

Laboratory chemistry blood urea nitrogen

Time frame:
Baseline, month 12
Reported as:
Mean · mmol/L
Blood Urea Nitrogen Change From Baseline at Month 12
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Blood Urea Nitrogen Change From Baseline at Month 120.27 ± 1.44-0.02 ± 1.50
SecondaryCreatinine Change From Baseline at Month 1

Laboratory chemistry creatinine

Time frame:
Baseline, month 1
Reported as:
Mean · umol/L
Creatinine Change From Baseline at Month 1
umol/LDenosumab - VialDenosumab - Pre-filled Syringe
Creatinine Change From Baseline at Month 10.24 ± 8.010.12 ± 7.76
SecondaryCreatinine Change From Baseline at Month 6

Laboratory chemistry creatinine

Time frame:
Baseline, month 6
Reported as:
Mean · umol/L
Creatinine Change From Baseline at Month 6
umol/LDenosumab - VialDenosumab - Pre-filled Syringe
Creatinine Change From Baseline at Month 6-0.19 ± 8.52-1.29 ± 8.23
SecondaryCreatinine Change From Baseline at Month 12

Laboratory chemistry creatinine

Time frame:
Baseline, month 12
Reported as:
Mean · umol/L
Creatinine Change From Baseline at Month 12
umol/LDenosumab - VialDenosumab - Pre-filled Syringe
Creatinine Change From Baseline at Month 121.40 ± 9.530.76 ± 8.28
SecondaryAspartate Amino Transferase Change From Baseline at Month 1

Laboratory chemistry aspartate amino transferase

Time frame:
Baseline, month 1
Reported as:
Mean · U/L
Aspartate Amino Transferase Change From Baseline at Month 1
U/LDenosumab - VialDenosumab - Pre-filled Syringe
Aspartate Amino Transferase Change From Baseline at Month 1-1.6 ± 13.00.4 ± 4.7
SecondaryAspartate Amino Transferase Change From Baseline at Month 6

Laboratory chemistry aspartate amino transferase

Time frame:
Baseline, month 6
Reported as:
Mean · U/L
Aspartate Amino Transferase Change From Baseline at Month 6
U/LDenosumab - VialDenosumab - Pre-filled Syringe
Aspartate Amino Transferase Change From Baseline at Month 6-1.6 ± 13.90.9 ± 7.7
SecondaryAspartate Amino Transferase Change From Baseline at Month 12

Laboratory chemistry aspartate amino transferase

Time frame:
Baseline, month 12
Reported as:
Mean · U/L
Aspartate Amino Transferase Change From Baseline at Month 12
U/LDenosumab - VialDenosumab - Pre-filled Syringe
Aspartate Amino Transferase Change From Baseline at Month 12-1.9 ± 13.50.2 ± 3.9
SecondaryAlanine Amino Transferase Change From Baseline at Month 1

Laboratory chemistry alanine amino transferase

Time frame:
Baseline, month 1
Reported as:
Mean · U/L
Alanine Amino Transferase Change From Baseline at Month 1
U/LDenosumab - VialDenosumab - Pre-filled Syringe
Alanine Amino Transferase Change From Baseline at Month 1-3.1 ± 25.70.5 ± 5.5
SecondaryAlanine Amino Transferase Change From Baseline at Month 6

Laboratory chemistry alanine amino transferase

Time frame:
Baseline, month 6
Reported as:
Mean · U/L
Alanine Amino Transferase Change From Baseline at Month 6
U/LDenosumab - VialDenosumab - Pre-filled Syringe
Alanine Amino Transferase Change From Baseline at Month 6-1.4 ± 27.84.2 ± 15.2
SecondaryAlanine Amino Transferase Change From Baseline at Month 12

Laboratory chemistry alanine amino transferase

Time frame:
Baseline, month 12
Reported as:
Mean · U/L
Alanine Amino Transferase Change From Baseline at Month 12
U/LDenosumab - VialDenosumab - Pre-filled Syringe
Alanine Amino Transferase Change From Baseline at Month 12-2.7 ± 28.81.5 ± 6.3
SecondaryTotal Bilirubin Change From Baseline at Month 1

Laboratory chemistry total bilirubin

Time frame:
Baseline, month 1
Reported as:
Mean · umol/L
Total Bilirubin Change From Baseline at Month 1
umol/LDenosumab - VialDenosumab - Pre-filled Syringe
Total Bilirubin Change From Baseline at Month 1-0.35 ± 2.53-0.02 ± 2.47
SecondaryTotal Bilirubin Change From Baseline at Month 6

Laboratory chemistry total bilirubin

Time frame:
Baseline, month 6
Reported as:
Mean · umol/L
Total Bilirubin Change From Baseline at Month 6
umol/LDenosumab - VialDenosumab - Pre-filled Syringe
Total Bilirubin Change From Baseline at Month 6-0.30 ± 2.54-0.20 ± 2.67
SecondaryTotal Bilirubin Change From Baseline at Month 12

Laboratory chemistry total bilirubin

Time frame:
Baseline, month 12
Reported as:
Mean · umol/L
Total Bilirubin Change From Baseline at Month 12
umol/LDenosumab - VialDenosumab - Pre-filled Syringe
Total Bilirubin Change From Baseline at Month 120.16 ± 2.680.64 ± 2.74
SecondaryAlbumin Change From Baseline at Month 1

Laboratory chemistry albumin

Time frame:
Baseline, month 1
Reported as:
Mean · g/L
Albumin Change From Baseline at Month 1
g/LDenosumab - VialDenosumab - Pre-filled Syringe
Albumin Change From Baseline at Month 1-0.46 ± 1.68-0.40 ± 2.05
SecondaryAlbumin Change From Baseline at Month 6

Laboratory chemistry albumin

Time frame:
Baseline, month 6
Reported as:
Mean · g/L
Albumin Change From Baseline at Month 6
g/LDenosumab - VialDenosumab - Pre-filled Syringe
Albumin Change From Baseline at Month 6-0.34 ± 1.92-0.51 ± 2.19
SecondaryAlbumin Change From Baseline at Month 12

Laboratory chemistry albumin

Time frame:
Baseline, month 12
Reported as:
Mean · g/L
Albumin Change From Baseline at Month 12
g/LDenosumab - VialDenosumab - Pre-filled Syringe
Albumin Change From Baseline at Month 12-0.26 ± 1.820 ± 2.03
SecondaryTotal Protein Change From Baseline at Month 1

Laboratory chemistry total protein

Time frame:
Baseline, month 1
Reported as:
Mean · g/L
Total Protein Change From Baseline at Month 1
g/LDenosumab - VialDenosumab - Pre-filled Syringe
Total Protein Change From Baseline at Month 1-0.59 ± 2.67-0.54 ± 3.45
SecondaryTotal Protein Change From Baseline at Month 6

Laboratory chemistry total protein

Time frame:
Baseline, month 6
Reported as:
Mean · g/L
Total Protein Change From Baseline at Month 6
g/LDenosumab - VialDenosumab - Pre-filled Syringe
Total Protein Change From Baseline at Month 6-0.58 ± 3.00-0.80 ± 3.33
SecondaryTotal Protein Change From Baseline at Month 12

Laboratory chemistry total protein

Time frame:
Baseline, month 12
Reported as:
Mean · g/L
Total Protein Change From Baseline at Month 12
g/LDenosumab - VialDenosumab - Pre-filled Syringe
Total Protein Change From Baseline at Month 12-1.35 ± 2.84-0.91 ± 3.28
SecondaryGlucose Change From Baseline at Month 1

Laboratory chemistry glucose

Time frame:
Baseline, month 1
Reported as:
Mean · mmol/L
Glucose Change From Baseline at Month 1
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Glucose Change From Baseline at Month 1-0.08 ± 1.270.03 ± 0.69
SecondaryGlucose Change From Baseline at Month 6

Laboratory chemistry glucose

Time frame:
Baseline, month 6
Reported as:
Mean · mmol/L
Glucose Change From Baseline at Month 6
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Glucose Change From Baseline at Month 6-0.08 ± 1.370.05 ± 0.80
SecondaryGlucose Change From Baseline at Month 12

Laboratory chemistry glucose

Time frame:
Baseline, month 12
Reported as:
Mean · mmol/L
Glucose Change From Baseline at Month 12
mmol/LDenosumab - VialDenosumab - Pre-filled Syringe
Glucose Change From Baseline at Month 12-0.06 ± 1.270.08 ± 0.92
SecondaryRed Blood Cells Change From Baseline at Month 1

Laboratory hematology red blood cells

Time frame:
Baseline, month 1
Reported as:
Mean · 10^12/L
Red Blood Cells Change From Baseline at Month 1
10^12/LDenosumab - VialDenosumab - Pre-filled Syringe
Red Blood Cells Change From Baseline at Month 10 ± 0.210.02 ± 0.23
SecondaryRed Blood Cells Change From Baseline at Month 6

Laboratory hematology red blood cells

Time frame:
Baseline, month 6
Reported as:
Mean · 10^12/L
Red Blood Cells Change From Baseline at Month 6
10^12/LDenosumab - VialDenosumab - Pre-filled Syringe
Red Blood Cells Change From Baseline at Month 60.04 ± 0.220.04 ± 0.22
SecondaryRed Blood Cells Change From Baseline at Month 12

Laboratory hematology red blood cells

Time frame:
Baseline, month 12
Reported as:
Mean · 10^12/L
Red Blood Cells Change From Baseline at Month 12
10^12/LDenosumab - VialDenosumab - Pre-filled Syringe
Red Blood Cells Change From Baseline at Month 12-0.01 ± 0.220.02 ± 0.23
SecondaryHemoglobin Change From Baseline at Month 1

Laboratory hematology hemoglobin

Time frame:
Baseline, month 1
Reported as:
Mean · g/L
Hemoglobin Change From Baseline at Month 1
g/LDenosumab - VialDenosumab - Pre-filled Syringe
Hemoglobin Change From Baseline at Month 1-0.97 ± 6.00-0.42 ± 6.24
SecondaryHemoglobin Change From Baseline at Month 6

Laboratory hematology hemoglobin

Time frame:
Baseline, month 6
Reported as:
Mean · g/L
Hemoglobin Change From Baseline at Month 6
g/LDenosumab - VialDenosumab - Pre-filled Syringe
Hemoglobin Change From Baseline at Month 60.84 ± 5.830.96 ± 6.34
SecondaryHemoglobin Change From Baseline at Month 12

Laboratory hematology hemoglobin

Time frame:
Baseline, month 12
Reported as:
Mean · g/L
Hemoglobin Change From Baseline at Month 12
g/LDenosumab - VialDenosumab - Pre-filled Syringe
Hemoglobin Change From Baseline at Month 12-1.74 ± 6.09-0.22 ± 6.62
SecondaryReticulocytes Change From Baseline at Month 1

Laboratory hematology reticulocytes

Time frame:
Baseline, month 1
Reported as:
Mean · 10^9/L
Reticulocytes Change From Baseline at Month 1
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Reticulocytes Change From Baseline at Month 13.70 ± 17.681.69 ± 17.41
SecondaryReticulocytes Change From Baseline at Month 6

Laboratory hematology reticulocytes

Time frame:
Baseline, month 6
Reported as:
Mean · 10^9/L
Reticulocytes Change From Baseline at Month 6
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Reticulocytes Change From Baseline at Month 619.54 ± 19.2215.21 ± 20.69
SecondaryReticulocytes Change From Baseline at Month 12

Laboratory hematology reticulocytes

Time frame:
Baseline, month 12
Reported as:
Mean · 10^9/L
Reticulocytes Change From Baseline at Month 12
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Reticulocytes Change From Baseline at Month 1219.09 ± 19.8215.08 ± 19.73
SecondaryPlatelets Change From Baseline at Month 1

Laboratory hematology platelets

Time frame:
Baseline, month 1
Reported as:
Mean · 10^9/L
Platelets Change From Baseline at Month 1
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Platelets Change From Baseline at Month 15.24 ± 33.202.48 ± 36.20
SecondaryPlatelets Change From Baseline at Month 6

Laboratory hematology platelets

Time frame:
Baseline, month 6
Reported as:
Mean · 10^9/L
Platelets Change From Baseline at Month 6
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Platelets Change From Baseline at Month 628.26 ± 32.1621.49 ± 53.82
SecondaryPlatelets Change From Baseline at Month 12

Laboratory hematology platelets

Time frame:
Baseline, month 12
Reported as:
Mean · 10^9/L
Platelets Change From Baseline at Month 12
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Platelets Change From Baseline at Month 1225.19 ± 42.0715.60 ± 41.82
SecondaryWhite Blood Cells Change From Baseline at Month 1

Laboratory hematology white blood cells

Time frame:
Baseline, month 1
Reported as:
Mean · 10^9/L
White Blood Cells Change From Baseline at Month 1
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
White Blood Cells Change From Baseline at Month 10.23 ± 1.070.01 ± 1.26
SecondaryWhite Blood Cells Change From Baseline at Month 6

Laboratory hematology white blood cells

Time frame:
Baseline, month 6
Reported as:
Mean · 10^9/L
White Blood Cells Change From Baseline at Month 6
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
White Blood Cells Change From Baseline at Month 60.22 ± 1.38-0.08 ± 1.47
SecondaryWhite Blood Cells Change From Baseline at Month 12

Laboratory hematology white blood cells

Time frame:
Baseline, month 12
Reported as:
Mean · 10^9/L
White Blood Cells Change From Baseline at Month 12
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
White Blood Cells Change From Baseline at Month 120.47 ± 1.380.24 ± 1.47
SecondaryTotal Neutrophils Change From Baseline at Month 1

Laboratory hematology total neutrophils

Time frame:
Baseline, month 1
Reported as:
Mean · 10^9/L
Total Neutrophils Change From Baseline at Month 1
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Total Neutrophils Change From Baseline at Month 10.11 ± 0.85-0.03 ± 1.10
SecondaryTotal Neutrophils Change From Baseline at Month 6

Laboratory hematology total neutrophils

Time frame:
Baseline, month 6
Reported as:
Mean · 10^9/L
Total Neutrophils Change From Baseline at Month 6
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Total Neutrophils Change From Baseline at Month 60.21 ± 1.23-0.02 ± 1.23
SecondaryTotal Neutrophils Change From Baseline at Month 12

Laboratory hematology total neutrophils

Time frame:
Baseline, month 12
Reported as:
Mean · 10^9/L
Total Neutrophils Change From Baseline at Month 12
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Total Neutrophils Change From Baseline at Month 120.38 ± 1.150.12 ± 1.18
SecondaryEosinophils Change From Baseline at Month 1

Laboratory hematology eosinophils

Time frame:
Baseline, month 1
Reported as:
Mean · 10^9/L
Eosinophils Change From Baseline at Month 1
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Eosinophils Change From Baseline at Month 1-0.002 ± 0.065-0.010 ± 0.059
SecondaryEosinophils Change From Baseline at Month 6

Laboratory hematology eosinophils

Time frame:
Baseline, month 6
Reported as:
Mean · 10^9/L
Eosinophils Change From Baseline at Month 6
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Eosinophils Change From Baseline at Month 60.020 ± 0.0750.013 ± 0.104
SecondaryEosinophils Change From Baseline at Month 12

Laboratory hematology eosinophils

Time frame:
Baseline, month 12
Reported as:
Mean · 10^9/L
Eosinophils Change From Baseline at Month 12
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Eosinophils Change From Baseline at Month 12-0.008 ± 0.0710.025 ± 0.436
SecondaryBasophils Change From Baseline at Month 1

Laboratory hematology basophils

Time frame:
Baseline, month 1
Reported as:
Mean · 10^9/L
Basophils Change From Baseline at Month 1
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Basophils Change From Baseline at Month 10.001 ± 0.0250 ± 0.022
SecondaryBasophils Change From Baseline at Month 6

Laboratory hematology basophils

Time frame:
Baseline, month 6
Reported as:
Mean · 10^9/L
Basophils Change From Baseline at Month 6
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Basophils Change From Baseline at Month 60.012 ± 0.0260.012 ± 0.028
SecondaryBasophils Change From Baseline at Month 12

Laboratory hematology basophils

Time frame:
Baseline, month 12
Reported as:
Mean · 10^9/L
Basophils Change From Baseline at Month 12
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Basophils Change From Baseline at Month 120.003 ± 0.0260.006 ± 0.024
SecondaryLymphocytes Change From Baseline at Month 1

Laboratory hematology lymphocytes

Time frame:
Baseline, month 1
Reported as:
Mean · 10^9/L
Lymphocytes Change From Baseline at Month 1
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Lymphocytes Change From Baseline at Month 10.12 ± 0.430.04 ± 0.40
SecondaryLymphocytes Change From Baseline at Month 6

Laboratory hematology lymphocytes

Time frame:
Baseline, month 6
Reported as:
Mean · 10^9/L
Lymphocytes Change From Baseline at Month 6
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Lymphocytes Change From Baseline at Month 60.01 ± 0.37-0.06 ± 0.45
SecondaryLymphocytes Change From Baseline at Month 12

Laboratory hematology lymphocytes

Time frame:
Baseline, month 12
Reported as:
Mean · 10^9/L
Lymphocytes Change From Baseline at Month 12
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Lymphocytes Change From Baseline at Month 120.08 ± 0.410.06 ± 0.36
SecondaryMonocytes Change From Baseline at Month 1

Laboratory hematology monocytes

Time frame:
Baseline, month 1
Reported as:
Mean · 10^9/L
Monocytes Change From Baseline at Month 1
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Monocytes Change From Baseline at Month 10 ± 0.120.01 ± 0.11
SecondaryMonocytes Change From Baseline at Month 6

Laboratory hematology monocytes

Time frame:
Baseline, month 6
Reported as:
Mean · 10^9/L
Monocytes Change From Baseline at Month 6
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Monocytes Change From Baseline at Month 6-0.03 ± 0.14-0.03 ± 0.10
SecondaryMonocytes Change From Baseline at Month 12

Laboratory hematology monocytes

Time frame:
Baseline, month 12
Reported as:
Mean · 10^9/L
Monocytes Change From Baseline at Month 12
10^9/LDenosumab - VialDenosumab - Pre-filled Syringe
Monocytes Change From Baseline at Month 120.01 ± 0.130.03 ± 0.14
SecondaryNumber of Participants With Laboratory Toxicity CTCAE Grade Greater or Equal to 3

Participants with laboratory toxicity grade 3 (severe) or 4 (life-threatening), based on the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.

Time frame:
Day 1 to Month 12
Reported as:
Number · Participants
Number of Participants With Laboratory Toxicity CTCAE Grade Greater or Equal to 3
ParticipantsDenosumab - VialDenosumab - Pre-filled Syringe
Number of patients with CTCAE grade 3 or 422
Sodium - Grade 3 below normal (< 130 - 120 mmol/L)01
Potassium - Grade 3 above normal (>6.0-7.0 mmol/L)01
Magnesium -Grade 3 above normal (>1.23-3.30mmol/L)20

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Denosumab - Vial—7/154 (4.5%)32/154 (20.8%)
Denosumab - Pre-filled Syringe—12/156 (7.7%)49/156 (31.4%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventDenosumab - VialDenosumab - Pre-filled Syringe
PneumoniaInfections and infestations0/1542/156
Atrial fibrillationCardiac disorders1/1541/156
Cardiac failure congestiveCardiac disorders1/1540/156
Gastrointestinal haemorrhageGastrointestinal disorders1/1540/156
OsteoarthritisMusculoskeletal and connective tissue disorders1/1541/156
Breast cancer stage INeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1540/156
Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1540/156
Vaginal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1540/156
Uterine prolapseReproductive system and breast disorders1/1540/156
DyspnoeaRespiratory, thoracic and mediastinal disorders1/1540/156
Most frequent other events
Most frequent other events
EventDenosumab - VialDenosumab - Pre-filled Syringe
ArthralgiaMusculoskeletal and connective tissue disorders11/15413/156
Back painMusculoskeletal and connective tissue disorders9/15411/156
Upper respiratory tract infectionInfections and infestations5/15410/156
SinusitisInfections and infestations5/1548/156
OsteoarthritisMusculoskeletal and connective tissue disorders3/1548/156
Pain in extremityMusculoskeletal and connective tissue disorders6/1548/156

Baseline characteristics

Age Continuous
Age Continuous(Years)Denosumab - VialDenosumab - Pre-filled SyringeTotal
Mean62.5 ± 8.562.9 ± 8.962.7 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Denosumab - VialDenosumab - Pre-filled SyringeTotal
Female155156311
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Denosumab - VialDenosumab - Pre-filled SyringeTotal
White or Caucasian124131255
Black or African American415
Hispanic or Latino241842
Asian336
Japanese022
American Indian or Alaska Native011
09

Study locations

No study locations are listed for this record.

10

References and documents

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Mar 2008 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 5 years 7 months after primary completion. A results delay was requested in Nov 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2007
First posted
Aug 13, 2007
Start
May 2007
Primary completionActual
Mar 2008
CompletionActual
Mar 2009
Results delay requested
Nov 23, 2009
Results first posted
Oct 31, 2013
Last update
Oct 31, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00515463
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 13, 2007
Start date
May 2007
Primary completion
Mar 2008
Completion
Mar 2009
Results posted
Oct 31, 2013
Last update
Oct 31, 2013

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion